MedPath

Endoscopic Ultrasound Elastography in Pancreatic Masses

Completed
Conditions
Pancreatic Adenocarcinoma
Chronic Pancreatitis
Registration Number
NCT00909103
Lead Sponsor
University of Medicine and Pharmacy Craiova
Brief Summary

The aim of the study is to assess elastography during EUS examinations of focal pancreatic masses, and to consequently differentiate benign versus malignant pancreatic masses in a prospective multi-center design.

Detailed Description

Ultrasound elastography is a recent ultrasound method used for the calculation of tissue elasticity distribution in real-time. The method allows the reconstruction of tissue elasticity (i.e. the elasticity modulus) and reveals directly the physical properties of the tissue, consequently showing different tissue hardness patterns that are determined by diseases. Tissue elastography can be easily performed real-time with conventional probes, including the linear EUS probes used for the examination of the pancreas. The calculation of tissue elasticity distribution is performed in real-time and the examination results are represented as transparent overlay colour images overimposed on the conventional gray-scale B-mode images.

Ultrasound elastography was previously used for the diagnosis of breast lesions, prostate cancer and thyroid nodules. However, the value of endoscopic ultrasound elastography for the diagnosis of pancreatic focal masses is not clear for the current moment, as some authors couldn't differentiate benign and malignant pancreatic tumors. Moreover, the intense fibrotic reaction and calcifications in chronic pancreatitis induce strain differences, and it is not clear if elastography is sensitive enough to detect them.

The study protocol is based on a semi-quantitative approach of EUS elastography data (movies) consisting of characterization of manually user-defined regions of interest, based on the hue histograms of the individual focal masses. Due to the inherent bias induced by selection of images from a dynamic sequence of EUS elastography, we have previously reported on the utility of using computer-aided diagnosis by averaging images from a dynamic sequence of EUS elastography. A special plugin (based on the ImageJ software, NIH, Bethesda, MD, USA) is used to compute hue histograms on average EUS elastography images, while the hue histograms values for each patient (0 to 255 values) are further used to classify the patients with benign and malignant lesions.

Ultrasound elastography will be performed during an usual EUS examination (7.5 MHz frequency), with two movies of 10 seconds recorded on the embedded HDD in order to minimize variability and to increase repeatability of acquisition. A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the elastography image on the left side will be used. The region of interest will be preferably larger than the focal mass, in order to include the surrounding structures. In order to minimize the human bias, all the post-processing and computer analysis of digital movies will be performed within the IT Center in Craiova, with all programmers and statisticians being blinded to the clinical, pathological and imaging data, with the exception of the average hue histogram values calculated from a second region of interest manually traced around the focal mass.

The study design is prospective, blinded and multi-center, comparing endoscopic ultrasound elastography (EUS-EG) results for the detection and characterization of focal pancreatic masses by using artificial intelligence techniques, in comparison with the gold standard represented by pathology. The study will be performed with the approval of the institutional board review of each center.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
285
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Value of endoscopic ultrasound elastography for the differential diagnoses of pancreatic masses.18 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (18)

Caritas-Krankenhaus

๐Ÿ‡ฉ๐Ÿ‡ช

Bad Mergentheim, Germany

University Clinic Mainz

๐Ÿ‡ฉ๐Ÿ‡ช

Mainz, Germany

HELIOS Klinikum Wuppertal, University of Witten/Herdecke

๐Ÿ‡ฉ๐Ÿ‡ช

Wuppertal, Germany

Erasme Medisch Centrum

๐Ÿ‡ณ๐Ÿ‡ฑ

Rotterdam, Netherlands

Newcastle Upon Tyne Hospitals

๐Ÿ‡ฌ๐Ÿ‡ง

Newcastle, United Kingdom

University Hospital

๐Ÿ‡ฉ๐Ÿ‡ฐ

Odense, Denmark

University of Haukeland

๐Ÿ‡ณ๐Ÿ‡ด

Bergen, Norway

University of Medicine and Pharmacy Craiova

๐Ÿ‡ท๐Ÿ‡ด

Craiova, Romania

University Hospital Santiago

๐Ÿ‡ช๐Ÿ‡ธ

Santiago, Spain

Universite Chatolique Louvain

๐Ÿ‡ง๐Ÿ‡ช

Brussels, Belgium

Institute Paoli Calmettes

๐Ÿ‡ซ๐Ÿ‡ท

Marseille, France

St. Josef Hospital

๐Ÿ‡ฉ๐Ÿ‡ช

Bochum, Germany

SRH Klinik

๐Ÿ‡ฉ๐Ÿ‡ช

Gera, Germany

Dr.Horst-Schmidt-Klinik

๐Ÿ‡ฉ๐Ÿ‡ช

Wiesbaden, Germany

Gentofte University Hospital

๐Ÿ‡ฉ๐Ÿ‡ฐ

Copenhagen, Denmark

Erasme University

๐Ÿ‡ง๐Ÿ‡ช

Brussels, Belgium

Hospital San Raffaele

๐Ÿ‡ฎ๐Ÿ‡น

Milan, Italy

Glasgow Royal Infirmary

๐Ÿ‡ฌ๐Ÿ‡ง

Glasgow, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath